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Background: Epidermal growth factor receptor (EGFR) is involved in the development of many human malignant
tumors and plays an important role in tumor growth and metastasis. Antagonists of EGFR can suppress the growth
of several malignancies; however, their therapeutic effect in adenoid cystic carcinoma (ACC) is controversial.
Results: The increased proliferation of two ACC cell lines induced by EGF-treatment was reversed by nimotuzumab.
Regardless of EGF stimulation, nimotuzumab-treated ACC cells were arrested in G1 phase and showed decreased
expression of Ki67. In addition, EGF activated the MAPK-dependent pathway and up-regulated the expression of
matrix metalloproteinase-9 and Snail, enhancing the invasive potential of an ACC cell line (ACC-M). The effects of
EGF were down-regulated by nimotuzumab treatment.
Conclusions: These results suggest that nimotuzumab can inhibit the growth and invasion of ACC cells induced by
EGF, probably through inactivation of ERK phosphorylation. Thus, nimotuzumab should be considered as a
promising novel agent for the treatment of ACC.
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Adenoid cystic carcinoma (ACC) is a common salivary
gland cancer subtype accounting for 22% of salivary
gland malignancies and 1% of all head and neck cancers
[1]. Perineural invasion, delayed onset of hematogenous
metastasis and poor response to traditional chemother-
apies are characteristics of this cancer. Local recurrence
and distant metastasis, in which extracellular matrix
(ECM) and basement membrane degradation are crucial,
are responsible for treatment failure. Currently, no sys-
temic therapy is available that effectively inhibits ACC
progression. Therefore, further understanding of the
development and progression of ACC and identification
of new molecular targets are of great importance.
Epidermal growth factor receptor (EGFR) is a member
of the ErbB receptor tyrosine kinase family, and upon
interacting with its ligand, it undergoes dimerization and* Correspondence: maohuangyi@hotmail.com
1Department of Head and Neck Oncology, West China College of
Stomatology, Sichuan University, No.14, Section 3, Ren Min Nan Road,
Chengdu 610041, China
Full list of author information is available at the end of the article
© 2013 Huang et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orautophosphorylation that trigger downstream signaling
cascades, such as phosphatidylinositol-3-kinase/Akt and
MAPK activation. This signaling pathway enhances
tumor cell proliferation, invasion, metastasis, and sur-
vival. It is well recognized that matrix metalloproteinase-
9 (MMP9), which is closely associated with tumor
invasion and metastasis in several human tumors, can
be inhibited by EGFR signaling pathway blockade [2-4].
Therefore, the EGFR signaling pathway is believed to
play a vital role in the progression and metastasis of
tumors, including ACC. Tyrosine kinase inhibitors (TKIs)
were first used to block EGFR-mediated signaling path-
ways. Regretfully, several studies implicated that TKI
treatment alone cannot achieve impressive clinical
outcomes, possibly because of the kinase-independent
functions of EGFR [5]. However, accumulating evidence
indicates that nimotuzumab, a humanized neutralizing G1
monoclonal antibody, can suppress cultured epithelial
cancer cell proliferation by causing cell cycle arrest. When
this antibody binds to the extracellular domain of EGFR, it
strongly inhibits EGFR-dependent cellular transformation
[6]. Although anticancer activity in advanced squamousLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ported [7,8], its role in ACC progression and metastasis is
still unclear.
In this study, we evaluated the effects of nimotuzumab
on the growth and invasion of ACC-2 and ACC-M,
using a tongue squamous cell carcinoma cell line
(Tca8113) as a positive control, and analyzed the pos-
sible downstream molecular targets and signaling path-
way [9-15].Results
Nimotuzumab inhibits cell proliferation in vitro
Immunohistochemistry was performed to measure the
expression of EGFR, MAPK, and Snail in three cell lines.
Both EGFR and P38 immunoreactivity were observed
mostly in the cytomembrane and cytoplasm, while Snail
expression was observed in cell nuclei. Positive staining
of three proteins was observed in all three cell lines
(Figure 1).
The growth curves showed that the inhibition of pro-
liferation plateaued at doses of 100, 200, and 100 μg/ml
nimotuzumab in ACC-2, ACC-M, and Tca8113 cells, re-
spectively. These concentrations of nimotuzumab were
used for all subsequent assays (Figure 2A).
Cells were immunolabeled with TRITC-labeled Ki-67
(red fluorescence) and the cell nuclei were stained with
DAPI (blue fluorescence). Ki-67-positive cells wereFigure 1 EGFR, P38, and Snail expression in ACCs and Tca8113 cell lin
expressed in ACC-2, ACC-M and Tca8113, respectively. Snail exhibited prefe
for the cytoplasm and cytomembrane. Magnification, ×400.defined as actively proliferating cells. The percentage of
Ki-67-positive cells of total DAPI-positive cells was
96.7%, 94.3% and 86% in Tca8113, ACC-M and
ACC-2 cells, respectively. However, this percentage
decreased to 67.9%, 70.2% and 80.3% in all three
nimotuzumab-treated cell lines, confirming that nimo-
tuzumab can suppress cancer cell proliferation in vitro
(Figure 2B, C).Nimotuzumab induced G1 phase arrest in ACC-M and
Tca8113 cells
To detect the effect of nimotuzumab on ACC cell proli-
feration, the cell cycle distribution of cells treated with
nimotuzumab (100 μg/ml for ACC-2 and Tca8113, 200 μg/
ml for ACC-M) and/or hEGF (40 ng/ml) in Tca8113 and
ACC cell lines were examined. Combined treatment of
ACC-M and Tca8113 cells with nimotuzumab and hEGF
resulted in a significant G1 phase arrest accompanied by a
reduction of the S phase fraction (Figure 3). After treat-
ment with nimotuzumab and hEGF, the percentages of
cells in the G1 phase increased from 41.7% to 51.6% in
ACC-M and from 56.8% to 61.55% in Tca8113cells. In the
absence of hEGF stimulation, nimotuzumab did not signifi-
cantly affect the cell cycle distribution (data not shown).
This confirmed the hypothesis that combined nimo-
tuzumab and hEGF treatment could suppress hEGF-
induced cell proliferation.es. Immunohistochemistry revealed that EGFR, P38 and Snail are
rences for nuclei, otherwise, both EGFR and P38 exhibited preferences
Figure 2 Nimotuzumab inhibits the Tca8113 and ACC cell proliferation. A: After treated with different concentration antibody in Tca8113 and
ACC cells the growth curve was drawn through CCK-8 assay. The anti-proliferative effect peaked at 100, 200, and 100 μg/ml in ACC-2, ACC-M, and
Tca8113 cells, respectively. B: The anti-proliferation was also evaluated by by Ki-67 immunostaining. Red fluorescence was reduced in all three cell lines,
specifically in Tca8113 and ACC-M cells. Magnification, ×200. C: Quantitative analysis of positive Ki-67 Tca8113 and ACCs cells in different groups.
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molecules
Serum-starved cells were incubated in medium (control) or
medium containing nimotuzumab for 72 h. qRT-PCR ana-
lysis demonstrated that Snail mRNA levels were 7.7 ± 2-,5.25 ± 1.7-, and 16 ± 2.2-fold higher in untreated Tca8113,
ACC-2 and ACC-M cell lines than in their treated counter-
parts, respectively. Conclusively, EGFR mRNA levels were
increased but without statistical significance in all three cell
lines. Keratinocyte Growth Factor (KGF) mRNA levels were
Figure 3 Effect of nimotuzumab on the cell cycle distribution of Tca8113 and ACC cells. After treated with medium or medium containing
nimotuzumab for 90 min followed by treatment with hEGF (40 ng/ml) for 15 min, cell nuclei were fixed, stained with PI, and analyzed by flow
cytometry. Cells were subdivided into two groups: hEGF group and hEGF+ nimotuzumab group. A: Representative histograms are shown that
combination treatment resulted in a 9.9% and 5% accumulation of ACC-M and Tca8113 cells in G1 phase. B: The statistical results of cell cycle
distribution of Tca8113 and ACC cells are shown.
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cells and up-regulated in ACC-M cells. EGFR mRNA levels
were 2.35 ± 0.35-, 3 ± 0.48-, and 4.3 ± 3-fold higher in
untreated Tca8113, ACC-2, and ACC-M cells than in their
treated counterparts, respectively. KGF mRNA levels were
0.6 ± 0.07-, 0.28 ± 0.07-, and 3.3 ± 0.22-fold higher in
untreated Tca8113, ACC-2, and ACC-M cells than in their
treated counterparts, respectively (Figure 4). P38 mRNA
levels were not affected by treatment in any cell line
observed (data not shown).
The protein levels of EGFR and its downstream mole-
cules were assessed by western blotting. In the first set
of studies, we determined whether the in vitro exposure
of cells to nimotuzumab decreased pEGFR protein
expression. Phosphorylated EGFR protein levels were
significantly decreased in nimotuzumab-treated Tca8113
and ACC-M cell lines compared with untreated cells.
For ACC-2, the phosphorylated EGFR expression level
was unchanged (Figure 5A, C). Interestingly, EGFRFigure 4 MMP9, EGFR, Snail, and KGF transcript levels in control
and nimotuzumab-treated cells. mRNA levels of MMP9, EGFR,
Snail, and KGF were measured by quantitative real-time RT-PCR,
normalized against GAPDH, and the indicated% induction or
reduction was compared with those in cells cocultured with
nimotuzumab. Although, the level of EGFR remained same, MMP9
and Snail expression in Tca8113 and ACC cells was inhibited by
nimotuzumab. Error bars indicate SDs, n=3. *, P<0.05.protein levels were down-regulated whole in the three
cell lines. It was reported that EGF activates ERKs
mainly through the Grb-2-SOS-Ras-Raf-MEK-ERK path-
way [16]. Consistent with previous findings, EGFR sig-
naling blockade significantly decreased ERK and pERK
production in Tca8113 and ACC-M cells (Figure 5A, C)
[17]. pERK and ERK protein levels were decreased and
increased by nimotuzumab treatment in ACC-2 cells,
respectively. We also examined P38 expression and
found that phosphorylated p38 did not change signifi-
cantly in all three cell lines regardless of nimotuzumab
treatment. Although nimotuzumab suppressed Snail
expression in all three cell lines, it did not affect KGF
expression in these cells (Figure 5B, C).
To evaluate the proposed mechanism of action of
nimotuzumab in vitro, we studied its ability to inhibit
EGF-induced tyrosine phosphorylation of EGFR and
MAPK by western blotting. Serum-starved cells were
treated with medium (control) or medium containing
nimotuzumab for 90 min followed by treatment with
hEGF (40 ng/ml) for 15 min. In agreement with previous
findings, besides decreased EGFR protein levels, EGF-
induced EGFR activation was abrogated by nimotu-
zumab treatment in ACC-M and ACC-2 cell lines,
resulting in pERK down-regulation [18]. Unexpectedly,
although ERK expression was decreased in ligand-
stimulated Tca8113 cells, its active form was increased.
No significant differences were found in P38 and pP38
expression in all three cell lines (Figure 6A, B).Nimotuzumab inhibits cell invasion
To investigate whether nimotuzumab could suppress the
invasive phenotypes of Tca8113 and ACC cells in vitro,
we conducted invasion assays using Matrigel-coated
Transwell chambers. All three cell lines could migrate
across the membrane. Among them Tca8113 and ACC-2
cells exhibited the highest and lowest capacity to
migrate, respectively. Pure cultured or co-cultured cells
on the upper chamber were allowed to migrate for 72 h
Figure 5 Nimotuzumab influences the expression of EGFR and its downstream molecules. A, B: Protein level of MMP-9, EGFR, pEGFR, ERK,
pERK, Snail, KGF, P-38, and pP38 in control and nimotuzumab- treated group were measured by Western blot. The GAPDH levels were used as
the internal controls. C: Densitometric analysis of the expression level of the same proteins relative to GAPDH expression. Error bars indicate
mean ± SD; n = 3 experiments; *P < 0.05.
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lity of Tca8113 was observed. The same tendency was
found in the ACC-M cell line (Figure 7A). The optical
density (OD) of the stained cells was measured at
570 nm (Figure 7B). To confirm whether nimotuzumabFigure 6 Nimotuzumab impeded the EGF-EGFR interaction. A: Serum-s
containing nimotuzumab for 90 min followed by treatment with hEGF (40
were assessed by Western blotting. GAPDH expression is also shown. B: De
GAPDH expression. Error bars indicate mean ± SD; n = 3 experiments; *P <regulated cell invasion by modulating MMP9 expression,
which is closely associated with tumor invasion and can
be inhibited by EGFR signaling blockade, qRT-PCR and
western blot analyses were performed. MMP9 mRNA
and protein levels were decreased significantly bytarved cells either were treated with medium (control) or medium
ng/ml) for 15 min. Protein level of MMP-9, EGFR, pEGFR, ERK, and pERK
nsitometric analysis of the expression of the same proteins relative to
0.05.
Figure 7 Nimotuzumab inhibits cell invasion. A: Starved cells
were allowed to invade the membrane for 72 h in the presence or
absence of nimotuzumab followed by the treatment with hEGF.
Tca8113 and ACC-M cell invasive ability were markedly inhibited by
nimotuzumab. Magnification,×200. B: The quantitative analysis of
invaded cells, which were eluted using 10% acetic acid, and the OD
value at 570 nm.
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5A, 6A).
Discussion
ACC preferentially metastasizes to the lungs, bone, liver,
and brain, unlike squamous cell head and neck cancer
(SCCHN) [19]. Local and distant recurrence can occur
concurrently irrespective of initial local control, sug-
gesting that distant and local recurrence is a separate
disease [20,21]. ACC is typically controlled through sur-
gery and postoperative adjuvant radiotherapy. Chemo-
therapy has also been attempted with extremely variable
and inconsistent outcomes [22]. To date, the most
effective chemotherapy treatment is the combination of
cyclophosphamide plus doxorubicin and cisplatin [23].Vascular EGFR (VEGFR)-targeted therapies have been
suggested to increase tumor invasiveness. VEGFR and
EGFR signaling pathways appear to be closely related,
casting doubt on the effectiveness of anti-EGFR therapy
[24,25]. Furthermore, the efficacy of small-molecule
tyrosine kinase inhibitors including gefitinib, imatinib,
and lapatinib has also been investigated with disappoint-
ing results [23]. Therefore, new therapeutic regimens
should be developed to treat advanced ACC. Many pre-
clinical studies suggest that nimotuzumab can be used
as part of a multimodality treatment scheme. Combined
radiation therapy and EGFR inhibition is considered a
standard concept for SCCHN [26]. Targeted therapies
such as nimotuzumab have also attracted attention for the
treatment of ACC. In the present study, nimotuzumab
inhibited tumor cell proliferation in vitro via an EGFR-
dependent signaling transduction mechanism.
To facilitate cell motility, the invading cells must alter
their cell-cell adhesion properties and the ECM environ-
ment. In this study, we observed that Tca8113, ACC-2
and ACC-M cell lines expressed MMP9, Snail, P38 and
EGFR in accordance with previous findings [27]. Unlike
vandetanib, which suppresses cell growth via a direct
pro-apoptotic mechanism, nimotuzumab inhibited cellu-
lar proliferation as confirmed by CCK-8 assay and Ki-67
immunofluorescence [18,25]. Nimotuzumab inhibited
the phosphorylation of EGFR and ERK, two downstream
effectors of the EGFR signaling pathway that promote
cellular proliferation and invasive potential. Further-
more, nimotuzumab down-regulated the mRNA and
protein expression of Snail, which can mediate EMT.
We hypothesized that binding of nimotuzumab to EGFR
impeded the interaction between EGF and EGFR, thus
inhibiting the activation of downstream cell signals and
preventing increased cellular proliferation and invasive
potential. P38 protein levels were not altered by nimo-
tuzumab in the nimotuzumab group or combination
group, suggesting that the inhibitory function of this
antibody did not involve P38 MAPK signaling.
Interestingly, EGFR mRNA in the experimental group
increased but was not statistically significant, compared
with the control group. However, EGFR protein levels
were significantly down-regulated in both the nimotu-
zumab group and combination group. We hypothesized
that the down-regulation was caused by nimotuzumab
blocking the binding site for the antibody used for
western blotting.Conclusions
Two unique features of ACCs are a predilection for
perineural infiltration and a low incidence of lymph
node metastasis. KGF expression was not affected by
nimotuzumab treatment. Thus, the predilection of ACC
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of other adhesion-related molecules.
MMPs facilitate cancer cell invasion and metastasis by
degrading ECM proteins. Under normal conditions,
MMP9 expression is low or absent in ACC cells. How-
ever, the EGFR signaling pathway has been implicated in
MMP9 up-regulation in SCCHN [27]. In this study,
MMP9 was expressed in both carcinoma cell lines. Its
expression was inhibited by nimotuzumab treatment. As
tumor cell invasion is MMP-dependent, MMPs likely
participate in the antitumor effects of nimotuzumab.
In summary, we demonstrated that nimotuzumab
could inhibit the growth and invasion of ACC cell lines
induced by EGF, probably through the inactivation of
ERK phosphorylation, suggesting that the in vivo efficacy
of nimotuzumab against metastatic ACC should be
examined. Nimotuzumab should be considered as a
promising novel agent for the treatment of ACC.Methods
Cell culture
ACC-2, ACC-M and Tca8113 cells were provided by the
State Key Laboratory of Oral Diseases, Sichuan University.
Cells were cultured with RPMI 1640 medium supple-
mented with 10% FBS, penicillin G (100 U/ml), and strep-
tomycin (100 μg/ml) at 37°C in a humidified atmosphere
of 5% CO2.Antibodies and reagents
Nimotuzumab was obtained from Biotech Pharma and
freshly diluted in serum-free RPMI 1640 to the designed
concentration for each experiment. Cell Counting Kit-8
(CCK-8) was obtained from Dojindo Laboratories. The
peroxidase-labeled secondary antibody and ECL system
were obtained from Millipore. Anti-phospho-EGFR,
anti-KGF, and anti-Slug primary antibodies were
obtained from Abcam. Anti-Snail, anti-P38/pP38, anti-
ERK/pERK, and hEGF were purchased from Cell Signal-
ing Technology. Anti-MMP-9 and mouse anti-Ki67 were
purchased from Zhongshan Goldenbridge Biotech-
nology. Antibodies to EGFR, SNAI 1, and P38 were
obtained from Bioworld Technology. Biotinylated se-
condary antibody, the horseradish peroxidase (HRP)-
streptavidin complex, and 3,3-diaminobenzidine were
obtained from ZSGB-BIO.Table 1 The primers for quantitative real-time RT-PCR




GAPDH CTTTGGTATCGTGGAAGGACTCCell proliferation assay
Cell proliferation assays were performed using CCK-8.
After exposure to different concentrations of nimotu-
zumab (0–400 μg/ml) for 72 h, the cells were reseeded
in 96-well plates at a density of 3×103 cells/well for 24 h.
The experimental group was subdivided into four groups
according to the nimotuzumab concentration: 400, 200,
100, and 50 μg/ml. Culture medium containing 10% FBS
was used as a negative control. After treatment, 10 μl of
CCK-8 solution were added to each well, followed by a
2-h incubation. The optical density (OD) at 490 nm
was measured to estimate the number of living cells
(Thermo Scientific Varioskan Flash).
Immunohistochemistry and immunofluorescence
Cells grown on coverslips in the presence of nimotu-
zumab for 72 h were fixed with 4% paraformaldehyde
for 15 min. The cells were further treated with 0.5%
Triton X-100 for 15 min for intracellular staining in the
case of Snail and Ki67.
Cells on the coverslips were stained using the standard
avidin-biotin complex procedure. After 0.3% hydrogen
peroxide was used to block endogenous peroxidase,
slices were blocked with goat serum. After separate in-
cubations with rabbit polyclonal anti-EGFR, anti-SNAI1,
and anti-P38, the slices were incubated with biotinylated
secondary antibody and the HRP-streptavidin complex
for 30 min at 37°C. Finally, the sections were stained
with 3,3-diaminobenzidine and counterstained with
hematoxylin. Goat serum was used as an isotype control.
Brown particles in the cytoplasm or nucleus indicated
positive expression.
The immunofluorescence of Ki-67 was assayed using
the 1:100-diluted mouse anti-Ki67 antibody. The sam-
ples were then washed and incubated with Alexa Fluor
594 goat anti-mouse IgM (Invitrogen, USA) for 1 h at
room temperature in the dark. The nuclei were visualized
using DAPI (Sigma). Samples were photographed with an
AxioCamMR monochrome digital camera mounted on a
Zeiss AxioImager Z1 microscope equipped with Zeiss
AxioVision 4 software (Zeiss, Nürnberg, Germany).
Quantitative real-time PCR
Total RNA was extracted from cells using Trizol reagent
(Invitrogen Life Technologies, Gaithersburg, MD)
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Prime Script RT Reagent kit following the manufac-
turer’s protocol (37°C for 15 min, 85°C for 5 s). All
primers sequences are shown Table 1. qRT-PCR was
performed using the Applied Biosystems 7300 Real Time
PCR System and SYBR Premix Ex Taq II™ system
(TaKaRa). The thermal cycling conditions were as fol-
lows: initial denaturing at 95°C for 30 s, followed by
40 cycles of denaturing at 95°C for 5 s and annealing at
60°C for 31 s. The housekeeping gene GAPDH was used
as an internal control. The relative quantification was
given by the threshold cycle (Ct) values, determined for
triplicate reactions for the experimental and control
groups. The relative gene expression level was calculated
using the 2−△△Ct method.
Western blot analysis and densitometry
After a 30-min lysis using lysis buffer (50 mM Tris–HCl,
pH 8.0; 5 mM EDTA; 150 mM NaCl; 0.5% Nonidet
P-40; 0.5 mM PMSF; 0.5 mM DTT), the supernatant
was collected by centrifugation at 14,000 rpm for
15 min. Approximately 50 μg of total protein from the
supernatant, as determined using the BCA protein assay
kit (keyGEN bioTECH, China), were resolved on a 10%
SDS-PAGE gel before being transferred to a PVDF
membrane using semi-dry (BioRad, Hercules, CA) and
wet transfer systems (BioRad mini-protean tetra cell).
Membranes were blocked in Tris-buffered saline (TBS:
150 mM NaCl; 50 mM Tris, pH 7.4) containing 5%
fat-free dried milk for 2 h and then incubated with
anti-EGFR/pEGFR, anti-KGF, anti-Snail, anti-P38/pP38,
anti-ERK/pERK, anti-MMP-9, or anti-GADPH primary
antibody overnight. After incubation with diluted HRP-
conjugated goat anti-rabbit and goat anti-mouse se-
condary antibodies for 60 min at room temperature,
membranes were washed in TBS containing 0.1%
Tween-20. Signals were visualized using the EasyECL
Western blot kit, and images were captured using a
Chemidoc XRS (BioRad). Densitometry was performed
using Quantity One software (BioRad, Hercules, CA).
Flow cytometry
The effect of nimotuzumab on cell cycle distribution
was determined by flow cytometry. Cells were starved in
serum-free medium for 24 h and then incubated with di-
luted hEGF and/or nimotuzumab. Untreated cells were
used as the negative control. Cells were washed with
PBS and fixed in 70% ethanol overnight at 4°C, followed
by treatment with 80 mg/ml RNaseA and 50 mg/ml PI
for 30 min and analysis using a Beckman FC500.
Cell invasion assay
The Transwell assay was performed using the QCM™
24-well Invasion Assay kit (Chemicon International,USA), based on the Boyden chamber principle. Starved
cells were resuspended in serum-free RPMI 1640
containing appropriate concentrations of nimotuzumab,
and 1×104 cells were added to the upper chamber. Five
hundred microliters of culture medium supplemented
with 10% FBS were added to the lower chamber as a
chemoattractant. The cell culture plates were incubated
for 72 h. After scraping off noninvaded cells and the
ECM gel from the interior of the insert with a cotton
swab, the polycarbonate membrane was stained with
0.1% crystal violet. Acetic acid (10%) was used to dis-
solve stained cells, and the eluent was quantified by
measuring the OD at 570 nm.Data statistics
All quantified data represent an average of at least three
samples. Data are expressed as the mean ± standard de-
viation (SD). Error bars represent the SD. Statistical ana-
lysis was performed using Student’s t-test, and P<0.05
indicated significant differences.
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